Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 5/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542614 | 0.82 | PTGS1 (0.41) | PARK7 | |
| SCHEMBL5544093 | 0.78 | ALDH1A1 (0.36) | PARK7ATAD2MAPT | |
| SCHEMBL5534874 | 0.77 | GRIA2 (0.38) | PARK7PAK1PKN1GRIA2GRIA1 | |
| SCHEMBL4753186 | 0.75 | ALDH1A1 (0.41) | MAPT | |
| SCHEMBL7436460 | 0.75 | ALDH1A1 (0.41) | MAPT | |
| SCHEMBL5545351 | 0.73 | PARK7 (0.34) | PARK7GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL20254404 | 0.68 | PARK7 (1.00) | PARK7 | |
| SCHEMBL5545985 | 0.67 | SRD5A1 (0.36) | PARK7GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL11529967 | 0.67 | BRD4 (0.55) | PARK7PAK1PKN1GRIA2BRD4 | |
| SCHEMBL20248930 | 0.66 | PARK7 (0.71) | PARK7PAK1PKN1BRD4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PARK7 4015/4885PAK1 2731/4885PKN1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.